Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 12/20 | 0.37 |
| ▸ | CPT2 | P23786 | 7/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 4/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | HTR7 | P34969 | 3/20 | 0.32 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787558 | 0.90 | ALDH1A1 (0.35) | CPT1ACPT2 | |
| SCHEMBL4678379 | 0.87 | CPT1A (0.34) | CPT1ACPT2CPT1BMAPT | |
| SCHEMBL6400638 | 0.87 | HCRTR2 (0.31) | CPT1ACPT2 | |
| SCHEMBL4686052 | 0.85 | CPT1A (0.37) | CPT1ACPT2CPT1BMAPTSMN1; SMN2 | |
| SCHEMBL4680643 | 0.85 | ENPP2 (0.39) | CPT1ACPT2 | |
| SCHEMBL6405908 | 0.76 | MAPT (0.36) | MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL4686055 | 0.73 | CPT1A (0.39) | CPT1ACPT2MAPTSMN1; SMN2 | |
| SCHEMBL4678381 | 0.72 | IDH1 (0.34) | CPT1ACPT2CPT1BMAPTSMN1; SMN2 | |
| SCHEMBL6400642 | 0.72 | IGF1R (0.34) | — | |
| SCHEMBL4680646 | 0.70 | ENPP2 (0.38) | CPT1ACPT2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1437349-B9 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2008-09-10 | — | — | EP | disclosed |
| EP-1437349-B1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2007-08-15 | — | — | EP | disclosed |
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2005-01-20 | — | — | US | disclosed |
| EP-1437349-A1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | XDH, SCO2, HAX1 | CPT1A 322/4885CPT2 674/4885CPT1B 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.